Key Changes in Share Count and Voting Power at Swedish Orphan Biovitrum AB

Changes in Number of Shares and Vote Count at Sobi

On September 30, 2026, Swedish Orphan Biovitrum AB (Sobi®) reported a total of 357,636,514 shares. This number includes 223,677 newly issued Class C shares, which were converted into common shares as outlined in the company's articles of association. These changes were made as part of Sobi's commitment to its long-term incentive program, benefiting permanent employees across the organization.

Overview of Sobi

Sobi is a prominent biopharmaceutical company dedicated to addressing the needs of individuals suffering from rare diseases. With a workforce of approximately 2,000 employees spread across Europe, North America, the Middle East, Asia, and Australia, Sobi has significantly impacted the biotechnology landscape. As of 2025, the company reported revenue reaching SEK 28 billion, showcasing robust growth and market presence. Sobi’s stock (STO: SOBI) is publicly traded on Nasdaq Stockholm, reflecting its established status in the financial markets. More information about Sobi can be found on sobi.com.

Details of the Share Increase

The issuance of the 223,677 Class C shares was specifically aimed at ensuring that the commitments of the All Employee Programme, a long-term incentive initiative designed to motivate and reward employees, were fulfilled. This approach reinforces Sobi's commitment to investing in its workforce and fostering a culture of collaboration and growth.

As of the end of September 2026, the organization holds 9,631,955 common shares, further solidifying its equity position in the biotechnology market.

The new shares and the associated voting rights reflect a clear strategy by Sobi to align employee incentives closely with the company’s solutions and objectives. This innovative program is intended to boost employee morale and retention by giving staff a stake in the company’s success.

Looking Ahead

As Sobi continues to advance its mission to transform the lives of those with rare diseases, regular updates on share counts and employee engagement strategies will be vital to maintaining investor confidence and organizational transparency. Stakeholders are encouraged to keep an eye on these developments as Sobi forges ahead in delivering innovative health solutions.

For additional inquiries or details regarding Sobi’s shareholder engagement or investor relations, please reach out to the Investor Relations department.

In conclusion, the changes in Sobi's share structure not only reflect its growth and commitment to employee welfare but also signify its ongoing endeavors to lead in the biopharma sector. Keeping abreast of Sobi’s announcements is essential for investors and stakeholders interested in the evolving landscape of biotechnology.